{"nctId":"NCT00003138","briefTitle":"Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes","startDateStruct":{"date":"1998-03-04","type":"ACTUAL"},"conditions":["Anemia","Myelodysplastic Syndromes"],"count":118,"armGroups":[{"label":"Supportive Care","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Transfusion"]},{"label":"Erythropoietin","type":"EXPERIMENTAL","interventionNames":["Biological: Erythropoietin","Biological: Filgrastim"]}],"interventions":[{"name":"Erythropoietin","otherNames":["r-HuEPO","EPO"]},{"name":"Filgrastim","otherNames":["G-CSF","Neupogen","Recombinant-methionyl human granulocyte colony-stimulating factor","Granulocyte colony-stimulating factor","r-methHuG-CSF"]},{"name":"Transfusion","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* Diagnosis of a myelodysplastic syndrome\n* Refractory anemia (RA)\n* RA with ringed sideroblasts\n* RA with excess blasts (RAEB). RAEB patients must have a bone marrow blast count of less than 20% and less than 5% blast forms on peripheral blood\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3\n* Platelet count greater than 30,000/mm\\^3 (without platelet transfusions)\n* Hematocrit less than 30% (pretransfusion)\n* Bilirubin less than 3 mg/dL\n* Blood urea nitrogen (BUN) less than 40 mg/dL or Creatinine less than 2.0 mg/dL\n* Prior epoetin alfa allowed provided dosage was less than 30,000 units per week for less than 1 month duration\n* At least 1 month since prior erythropoietin\n* At least 2 months since prior recombinant growth factor\n* At least 2 months since prior chemotherapy for other malignancy or autoimmune disease\n* At least 2 weeks since prior androgen or steroids for treatment of myelodysplastic syndromes\n\nExclusion Criteria:\n\n* RAEB in transformation\n* Chronic myelomonocytic leukemia\n* Splenomegaly greater than 6 cm below the left costal margin or greater than 3 times normal size\n* Uncontrolled hypertension\n* Sensitivity to E. coli-derived proteins\n* Sensitivity to epoetin alfa or any of its components (e.g., human albumin)\n* Documented iron deficiency. If marrow iron stain is not available, the transferrin saturation must be greater than 20% or ferritin greater than 100 ng/dL\n* Active infection or bleeding\n* Other uncontrolled malignancy\n* Pregnant or nursing. Fertile patients must use effective contraception.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients Free of Transfusion at 4 Months","description":"Whether a patient required transfusion or not at 4 months was recorded.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.459","spread":null},{"groupId":"OG001","value":"0.714","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Time from randomization to death from any cause. Patients alive at the time of analysis were censored at the date of last contact.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life- Total Functional Assessment of Cancer Therapy - General (FACT-G) Score at 4 Months","description":"The FACT-G scale has 4 dimensions, including physical well-being, social/family well-being, emotional well-being, and functional well-being. The score for each subscale was added together to obtain the total FACT-G score that was evaluated on this study. The total FACT-G score ranges from 0 to 108 with higher scores reflecting better quality of life. It was administered at the time of study entry, every 4 months for the first year, and at the time patient went off treatment. Due to limited data after 4 months on treatment, the analysis was restricted to the four-month time point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":"15.77"},{"groupId":"OG001","value":"84.33","spread":"14.75"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":56},"commonTop":["Fatigue","Diarrhea","Nausea","Neuropathy-clinical","Skin"]}}}